α-MSH (11-13) acetate
Based on 1 Customer Validation
α-MSH (11-13) (ACTH-(11-13)) acetate is a C-terminal tripeptide of α-MSH that can cross the blood-brain barrier. α-MSH (11-13) acetate exhibits antipyretic, anti-inflammatory, and antibacterial activities. α-MSH (11-13) acetate also exerts neuroprotective effects after traumatic brain injury by inhibiting excessive activation of microglia and reducing neuronal apoptosis. α-MSH (11-13) acetate can be used in research related to traumatic brain injury, fever, and bacterial infections.
For research use only. We do not sell to patients.
- Purity: 99.31%
- CAS No.: 2828433-34-5
- Formula: C18H34N4O6
- Molecular Weight:402.49
-
Storage:
Sealed storage, away from moisture.
Powder -80°C, 2 years , -20°C, 1 year* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Biological Activity
α-MSH (11-13) acetate induces MC1R-dependent calcium signaling and inhibits TNF-α-stimulated NF-κB activation in MC1R-transfected CHO-K1 cells[1].
α-MSH (11-13) acetate inhibits the production of TNF-α, IL-6, and nitric oxide in LPS (HY-D1056)-stimulated mouse microglial cell cultures[1].
α-MSH (11-13) (0-0.1 mM; 2 h) acetate significantly inhibits colony formation of clinical methicillin-resistant Staphylococcus aureus/Candida albicans isolates[3].
α-MSH (11-13) (1 μM; 3 min) acetate significantly increases the level of cAMP accumulation in permeabilized Candida albicans[3].
α-MSH (11-13) (0-0.1 mM; 2 h) acetate enhances the killing activity of human neutrophils against clinical isolates of methicillin-resistant Staphylococcus aureus and Candida albicans[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
α-MSH (11-13) (0.5-200 mg; intracerebroventricular injection, intravenous injection; single administration) acetate dose-dependently reduces leukocytic pyrogen-induced fever in rabbits after central or peripheral administration[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:C57Bl/6N (2-month-old male, 21-35 g, traumatic brain injury induced via controlled cortical impact)[1]
-
Dosage:1 mg/kg
-
Administration:i.p.; single dose
-
Result:Reduced secondary brain contusion volume by 24%.
Decreased microglial activation.
Lowered number of apoptotic neurons.
Did not significantly change neurological severity score.
-
Animal Model:New Zealand white (adult)[2]
-
Dosage:0.5 mg (i.c.v.); 1.0 mg (i.c.v.); 2.0 mg (i.c.v.); 2 mg (i.v.); 20 mg (i.v.); 200 mg (i.v.)
-
Administration:i.c.v.; single dose; i.v.; single dose
-
Result:Produced average percent reductions of the area under the control fever curve (over 1.5 hr) of 24% (0.5 mg i.c.v.), 31% (1.0 mg i.c.v.), and 48% (2.0 mg i.c.v.), with each dose significantly more antipyretic than lower doses.
Produced average percent reductions of the area under the control fever curve (over 1.5 hr) of 34% (2 mg i.v.), 27% (20 mg i.v.), and 67% (200 mg i.v.).
Had no effect on body temperature when 200 mg i.v.
dose was administered to afebrile rabbits.
Chemical Information
-
CAS No. 2828433-34-5
-
Appearance Solid
-
Molecular Weight 402.49
-
Formula C18H34N4O6
-
Color White to off-white
-
Synonyms
ACTH-(11-13) acetate; Lys-Pro-Val acetate; H-Lys-Pro-Val-OH acetate
-
Sequence
Lys-Pro-Val
-
Sequence Shortening
KPV
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Sealed storage, away from moisture
Powder -80°C 2 years -20°C 1 year * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Solvent & Solubility
DMSO : 100 mg/mL (248.45 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
H2O : 100 mg/mL (248.45 mM; Need ultrasonic)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (6.21 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Working solution concentration: 0.22 mg/mL
This product has good water solubility, please refer to the measured solubility data in water/PBS/Saline for details.
Purity & Documentation
-
Data Sheet (282 KB)
-
SDS (254 KB)
- English - EN (254 KB)
- Français - FR (254 KB)
- Deutsch - DE (254 KB)
- Norwegian - NO (254 KB)
- Español - ES (254 KB)
- Swedish - SV (254 KB)
- Italian - IT (254 KB)
- Korean - KR (254 KB)
- Portuguese - PT (254 KB)
-
Handling Instructions (2659 KB)
References
[1]. Schaible EV, et al. Single administration of tripeptide α-MSH(11-13) attenuates brain damage by reduced inflammation and apoptosis after experimental traumatic brain injury in mice. PLoS One. 2013;8(8):e71056. Published 2013 Aug 5. [Content Brief]
[2]. Richards DB, et al. Effect of alpha-MSH 11-13 (lysine-proline-valine) on fever in the rabbit. Peptides. 1984;5(4):815-817. [Content Brief]
[3]. Cutuli M, et al. Antimicrobial effects of alpha-MSH peptides. J Leukoc Biol. 2000 Feb;67(2):233-9. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO / H2O | 1 mM | 2.4845 mL | 12.4227 mL | 24.8453 mL | 62.1133 mL |
| 5 mM | 0.4969 mL | 2.4845 mL | 4.9691 mL | 12.4227 mL | |
| 10 mM | 0.2485 mL | 1.2423 mL | 2.4845 mL | 6.2113 mL | |
| 15 mM | 0.1656 mL | 0.8282 mL | 1.6564 mL | 4.1409 mL | |
| 20 mM | 0.1242 mL | 0.6211 mL | 1.2423 mL | 3.1057 mL | |
| 25 mM | 0.0994 mL | 0.4969 mL | 0.9938 mL | 2.4845 mL | |
| 30 mM | 0.0828 mL | 0.4141 mL | 0.8282 mL | 2.0704 mL | |
| 40 mM | 0.0621 mL | 0.3106 mL | 0.6211 mL | 1.5528 mL | |
| 50 mM | 0.0497 mL | 0.2485 mL | 0.4969 mL | 1.2423 mL | |
| 60 mM | 0.0414 mL | 0.2070 mL | 0.4141 mL | 1.0352 mL | |
| 80 mM | 0.0311 mL | 0.1553 mL | 0.3106 mL | 0.7764 mL | |
| 100 mM | 0.0248 mL | 0.1242 mL | 0.2485 mL | 0.6211 mL |
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
- α-MSH (11-13)
- 2828433-34-5
- ACTH-(11-13)
- Lys-Pro-Val
- H-Lys-Pro-Val-OH
- Melanocortin Receptor
- Interleukin Related
- Bacterial
- NF-κB
- Apoptosis
- HaCaT human keratinocytes
- Staphylococcus aureus
- human immunodeficiency virus
- neutrophils
- neuronal apoptosis
- Candida albicans
- keratinocytes
- microglial activation
- MC-1R-stably transfected CHO-K1 cells
- melanocortin-1 receptor
- Inhibitor
- inhibitor
- inhibit